Novo Nordisk Commits $2.7 Billion to Artificial Intelligence-Driven Drug Development

Eli Lilly Partners with Insilico Medicine for AI-Powered Drug Discovery

Eli Lilly, a leading US pharmaceutical company, has entered into a strategic partnership with Insilico Medicine, a Hong Kong-listed biotech firm, to leverage artificial intelligence (AI) for drug discovery.

According to a recent stock market filing, the value of the deal could reach up to $2.75 billion. Under the agreement, Eli Lilly and Insilico Medicine will collaborate to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas using Insilico's AI engine.

This new partnership builds on existing collaborations between the two companies, which had previously signed a software licensing agreement in 2023. The rapidly evolving field of generative AI holds significant promise for various sectors, including medicine, due to its ability to process vast amounts of data at a speed surpassing human capabilities.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

As a result of the announcement, Insilico Medicine shares experienced a significant surge, trading up 6.5% in Hong Kong during morning trade on Monday, following an initial spike of nearly 15% at the open.

Under the terms of the deal, Insilico Medicine will receive an upfront payment of $115 million. The partnership will focus on multiple research and development programs, with Eli Lilly selecting the targets for investigation.